Haemodialysis Vascular Access — Fistula-First Arithmetic with Catheter Honesty, Maturation Odds, Steal and Surveillance Verdicts, and the Buttonhole Infection Price

A 64-year-old man starting dialysis with a catheter, a 78-year-old woman with small forearm veins, and a 65-year-old woman with a painful pale hand after a brachial fistula. One needs a fistula attempt with conversion arithmetic, one needs an elderly-specific access decision with catheter-dependence honesty, and one needs steal graded and treated by the DRIL-first ladder. The examiner will watch you quote the access-type mortality split with its confounding caveat, price maturation failure before promising a fistula, stage basilic options, choose steal treatment by preservation rates, and split surveillance benefit between fistulas and grafts — with every number taken from the papers named beside it.^{[1][6][18][29][33][38]}

Overview & Definition — fistula, graft, catheter and the Life-Plan

Haemodialysis vascular access is the surgically created circuit — autogenous fistula, prosthetic graft or tunneled catheter — that connects the patient to the machine, and the 2019 KDOQI update organises every decision around the end-stage kidney disease Life-Plan: access choice matched to the patient's whole dialysis future, with new targets for fistulas, grafts and catheters, complication management and GRADE-appraised statements carrying rationale, monitoring and implementation guidance.^[57] The hierarchy the examiner expects is fistula over graft over catheter on outcomes — catheters carry 1.53-fold mortality, 2.12-fold fatal infection and 1.38-fold cardiovascular events against fistulas across 62 cohorts with 586,337 participants, while grafts sit between at 1.18 and 1.36 with cardiovascular risk indistinguishable from fistulas.^[1] The hierarchy's honesty clause follows at once: the only randomised catheter-versus-fistula comparison is a feasibility pilot in patients 55 and older with no harm signal from the catheter strategy and most outcomes favouring catheters — because no completed efficacy trial exists, every observational hazard ratio is counselled with confounding attached and strong patient preferences decide with the surgeon, not for the patient.^[6] The strategic arc fits one sentence: attempt the fistula first where maturation odds justify it, climb distal-to-proximal through staged basilic options, survey fistula flow with preemptive repair, cannulate rope-ladder in-centre, lock or exchange catheters by studied regimens, and treat steal by preservation rates — with the elderly priced separately at every step.^{[7][29][38][45][52][33]}

Configurations — the distal-to-proximal ladder with staged basilic verdicts

Climb radiocephalic first: the distal forearm fistula preserves proximal sites, and a matched 194-patient comparison shows why surgeons still start there despite inferior numbers — brachiocephalic vessels run larger with intraoperative flow at 492.5 against 307.3 mL/min and primary patency at 88.7 against 62.9%, yet radiocephalic remains the default because proximal sacrifice is forever while distal failure is merely a delay.^[23] Climb brachiocephalic second, then brachiobasilic with staging honesty: the only randomised staging trial stopped early when primary transposition matured in 3 of 9 against 7 of 7 staged at 10 weeks — trading 54 against 97 days to first dialysis — while the pooled analysis finds no failure or 1-year patency difference with only 2-year primary patency favouring two-stage at RR 2.50, and the 2648-patient VQI analysis finds adjusted 12-month patency identical with swelling significantly lower after two-stage at aHR 0.35.^[29][30][31] Superficialise by elevation where possible: tunnel transposition trails elevation at 6 months (OR 0.43) with 12- and 24-month patency identical — so the smaller dissection wins early without costing late.^[32] Place graft where autogenous options fail: transposed fistulas beat grafts on thrombosis (8.69 vs 18.80%, OR 0.34), infection (2.12 vs 8.38%, OR 0.20) and all patency measures — yet the 63-study 357 333-patient pooling still grants fistulas higher primary failure (OR 2.05 alongside the patency wins) — so graft is the honest fallback, not the failed plan.^[28][27] Cannulate grafts early where designed: early-cannulation designs permit needling within 72 hours with 12-month secondary patency from 70.5 to 85.8% across four graft families — the catheter bridge shortened by manufacture rather than by hope.^[66]

Populations & Denominators — the cohorts that frame every decision

The access-type cohorts run Ravani 62 cohorts with 586,337 participants, CHOICE 616 incident patients with 1084 accesses over 1381 person-years, DOPPS-conversion 4532 incident patients, Scotland 2666 haemodialysis patients with 873 deaths, Ng 2635 incident patients with predialysis care, Quinn pilot randomisation in 12 Canadian and Australian centres, Drew decision analysis across age-sex-diabetes phenotypes, and Rosas cost-utility with maturation-rate thresholds.^{[1][2][3][4][5][6][7][8]} The elderly cohorts contribute DeSilva 82,202 patients 70 and older, Lee-predialysis 3418 patients 70 and older, Lee-AVF-vs-AVG 9458 patients 67 and older, Lee-tradeoffs the same 9458 with intervention arithmetic, Lyu-dependence 14,532 fistulas with 3,391 grafts, Lyu-target-trial 19,867 with weighting and instrumental-variable analysis, and the 75-plus pooling of 12 studies.^{[9][10][11][12][13][14][15]} The maturation cohorts contribute Feldman 348 prospective fistulas, Voorzaat 1383 fistulas with 273 grafts across 8 Dutch hospitals, Woodside 45,087 fistulas in 39,820 US patients, HFM 491 single-stage fistulas across 7 centres, Salih 38 studies, Fisher 363 creations, and Kosa 4 imaging trials with 450 participants.^{[16][17][18][19][20][21][22]} The configuration cohorts contribute Ryu 194 matched forearm-versus-arm fistulas, Hu 84 modified-versus-traditional, Lu 148 basilic fistulas with 157 grafts over 12 years, Hajibandeh 15 studies with 118,434 patients, Yang 63 studies with 357 333 patients, Tang 33 trials with 6430 participants, Kakkos 16 randomised transpositions, Wee pooled staging trials, Tan 2648 VQI brachiobasilics, and Koudounas 543 tunnel-versus-elevation patients.^{[23][24][25][26][27][28][29][30][31][32]} The steal cohorts contribute Leake 201 patients with 218 episodes over 10 years, Gupta 114 ischaemic steals with 100 comparison procedures, Misskey 2035 autogenous constructions with 58 grade-3 ischaemias, Weaver 66 DRILs with conduit comparison, and Turner 110 small-versus-regular anastomoses.^{[33][34][35][36][37]} The surveillance cohorts contribute Cochrane 14 studies with 1390 participants, Ravani-MA the same 14 trials, Aragoncillo two randomised flow trials with 196 and 207 fistulas, Ali 10 trials with 1430 patients, Moist 112 graft patients, and Tessitore the threshold trial.^{[38][39][40][41][42][43][44]} The cannulation cohorts contribute Wong 23 studies from 1044 citations, Wang 15 trials, Lyman national surveillance with 271,980 buttonhole patient-months, and Muir 90 home patients over 3,765 fistula-months — with catheter cohorts from Poinen 1041 Canadians, Almenara 406 catheters over 14 years, Arslan 171 patients, Campos 204 randomised catheters, Moore 555 patients with 1,350 catheters, and Beathard 114 bacteremia episodes.^{[45][46][47][48][49][50][51][52][53][54]} The strategy cohorts close the set: Shingarev 322 fistulas-or-grafts after catheter start, Asif 28 pacemaker stenoses across centres, KDOQI GRADE Life-Plan, Sequeira controversies, Aitken 126 randomised anaesthetics with 12-month follow-up, Cerneviciute 4 trials with 286 fistulas, Tanner 15 drug trials with 2230 participants, Fonseca 14 thrombosis trials with 1176 participants, Kuhan 6 trials with 573 occluded grafts, Brooke 720 matured fistulas with 407 intervened, Shakarchi 19 early-graft studies, and three endovascular-fistula poolings to 1863 patients.^{[55][56][57][58][59][60][61][62][63][64][65][66][67][68][69]}

Clinical Presentation — the silent fistula, the pale hand, the febrile catheter

The failing-to-mature fistula declares through silence: no thrill, no bruit, no cannulation — and nationally more than a third of fistulas are never used with barely half working within 4 months, while Dutch nonmaturation runs 24% for forearm and 11% for upper-arm builds against 6% graft failure — so the quiet fistula at 6 weeks is the commonest presentation in access surgery.^[18][17] The steal hand declares through pain, pallor and tissue loss: brachial-artery-based circuits cause 87% of episodes in the 10-year series with women at 62% and diabetes at 61%, grade-2 and grade-3 disease split evenly, and tissue loss driving three of five severe interventions — so the painful pale hand after a brachial fistula is steal until proven otherwise.^[33][35] The infected catheter declares through fever and bacteremia: 1-year bacteremia risk 9% with malfunction 15% and stenosis 2% in Canadians, 0.40 per 1000 catheter-days over 14 Spanish years with 30-day mortality 8.7% from the first bacteremia, and femoral site with diabetes and age as the risk cluster — so the febrile catheter patient is bacteremic until cultures say otherwise.^[49][50][51] The stenosed access declares through flow and pressure: falling Qa below 500 mL/min or by more than 25%, rising venous pressures, prolonged bleeding and difficult cannulation — the surveillance triggers that halve fistula thrombosis when acted on.^[40][42]

Differential Diagnosis — maturation lag, stenosis, steal, infection

Split maturation lag from primary failure first: HFM shows 90.2% of fistulas reach attempted cannulation with 97.1% eventual success and 88.6% overall maturation — yet half need an intervention to get there — so the 6-week quiet fistula earns assisted maturation (balloon success 60% in one series) before abandonment, and only 23% are never used at all.^[19][21] Split steal from ischaemia before treating: grade-3 disease concentrates tissue loss at 61% with rest pain at 39%, diabetes in 86% and symptomatic peripheral disease in 63% — so the diabetic with a brachial fistula and a painful hand gets steal graded, not atherosclerosis assumed.^[35][34] Split buttonhole infection from background bacteremia before blaming technique: national surveillance attributes 2466 bloodstream infections to buttonhole months with S. aureus in half and 37% hospitalised — against rope-ladder at adjusted 2.6-fold bloodstream and 1.5-fold local risk — so the febrile buttonhole fistula is technique-related until proven otherwise.^[47] Split central stenosis from access stenosis when flows fall bilaterally: ipsilateral catheters halve cumulative fistula survival, pacemaker leads stenose centrally with angioplasty holding only 18% primary patency at 6 months against 95% secondary — so arm swelling with a device or catheter history earns central imaging, not just fistulography.^[55][56]

Name the failure mode aloud before booking the fix — the viva rewards the candidate who separates what maturation decides from what stenosis, steal and infection decide.^[16][38][33]

Clinical & Bedside Assessment — thrill, pulses, Allen, maturation signs

Feel the thrill and listen along the whole circuit at every dialysis: loss of thrill localises thrombosis, a pulsatile mass with absent thrill marks outflow stenosis, and prolonged post-needle bleeding with rising venous pressures completes the bedside stenosis set that surveillance trials act on.^[40][44] Examine the hand before and after every brachial access: digital pressures, capillary return and Allen competence at baseline — because steal strikes up to 10% of creations with brachial origin in two-thirds of cases, and the documented examination is what justifies urgent DRIL over observation.^[37][34] Inspect every catheter exit site and tunnel at every session: minimal symptoms with a clean tunnel earn guidewire exchange within 48 hours of antibiotics with 87.8% cure, tunnel infection earns new-tunnel exchange at 75%, and severe sepsis earns removal with delayed replacement at 86.5% — the bedside appearance chooses the catheter operation.^[54] Measure maturation against function, not thrill alone: attempted cannulation in 9 of 10 with eventual success in 97% of attempted, unassisted maturation in 61.2% with assisted in 27.4% — so the 6-week examination books ultrasound and assistance rather than declaring failure.^[19] Record the predictors that price the attempt: stroke history, advancing age and dialysis dependence lower maturation odds; female sex, small vessels, low albumin, diabetes and low pressures predict early failure; vein below 2.5 mm with female sex and vascular disease flags Dutch nonmaturation — so the small-veined elderly diabetic woman hears the numbers before the knife.^[16][20][17]

Investigations — duplex mapping with Cochrane honesty, flow thresholds, fistulography

Map vessels by duplex before every creation — then quote the Cochrane honesty: routine preoperative imaging across 4 small trials changed neither creation (RR 1.06), 6-month maturation (RR 1.11), successful use (RR 1.12) nor catheter starts (RR 0.66) — so mapping chooses the configuration without promising to improve the outcome.^[22] Measure access flow where fistulas are concerned: Qa below 500 mL/min or a 25% fall triggers fistulography with preemptive repair halving thrombosis (RR 0.79 overall, 0.5 in fistulas) and halving fistula loss (RR 0.5) — while grafts gain nothing on thrombosis (RR 0.95) or loss (RR 0.9), so flow surveillance is a fistula programme, never a graft one.^[38][40][41] Act on the threshold the small trial found: repair above 500 mL/min cuts thrombosis 3-fold (RR 0.37) and loss nearly 3-fold (RR 0.36) against waiting for 400 — the number that turns surveillance from ritual into salvage.^[44] Image centrally when the arm swells: ipsilateral catheter halves cumulative fistula survival (HR 2.48), and lead-induced stenosis needs 2.1 angioplasties yearly to hold 95% secondary patency against 18% primary — so central veins are imaged, not assumed.^[55][56]

Management — Access choice: fistula-first arithmetic with elderly pricing

Give the incident arithmetic exactly: DOPPS 4532 patients start 69.2% catheter, 17.6% graft, 13.1% fistula — 22% of permanent accesses fail at a median 62 to 84 days while 59% of catheters convert to permanent access — and conversion to permanent access cuts mortality hazard to 0.69 while conversion back to catheter raises it to 1.81, persisting across demographics and unit practices.^[3] Give the CHOICE split exactly: 66% catheter, 20% graft, 14% fistula at initiation moving to 34/40/26% by 6 months — with annual mortality 11.7% fistula, 14.2% graft, 16.1% catheter and adjusted death hazards 1.5 for catheter and 1.2 for graft against fistula, the catheter penalty concentrating in men.^[2] Give the Scottish confirmation exactly: 2666 patients with 873 deaths — tunnelled-catheter-only follow-up carries mortality hazard 1.83 to 2.08 across all exposure strata, cardiovascular death 2.20 to 2.95, infection death 3.10 to 3.63, and 6.9-fold septicaemia-death odds against fistula-or-graft — with hospitalisation burden matching at adjusted 1.30 all-cause, 1.47 infection and 1.49 access-related for catheters.^[4][5] Give the decision analysis exactly: fistula-attempt beats graft and catheter on mortality and cost for most phenotypes, especially younger non-diabetic men — while diabetic women and elderly diabetic men come out similar whatever the strategy — so the attempt is the default, not the dogma.^[7] Give the cost-utility exactly: fistula-first yields 2.19 against 2.06 QALYs at $9389 per QALY, cost-effective while maturation probability exceeds 36% and dominant above 69% — the number that converts maturation odds into strategy.^[8]

Price the elderly separately: fistula benefit survives past 70 at hazard 0.56, 0.55 and 0.69 across the three age bands — but graft benefit dies past 90 (HR 0.83, ns) and vanishes with malignancy or peripheral disease in the 81-to-90 band — so the oldest and sickest hear uncertainty, not orders.^[9] Price predialysis creation: two-thirds to 71% of elderly creations reach dialysis within 2 years — yet only half start with a working access, nearly half of fistulas are placed within 90 days of need, and catheter dependence at initiation runs 46.0% after fistula against 28.5% after graft — so early placement without timely maturation is catheter dependence by another name.^[10] Price fistula-versus-graft in the elderly: fistulas cost more catheter months every month for 6 months — yet earn fewer infection hospitalisations (0.93), fewer bacteremias (0.90) and lower death (HR 0.76) — while grafts fail less early (45 vs 51% unsuccessful, HR 1.86) with fewer make-it-work interventions (23 vs 42%, OR 2.66).^[11][12] Price dependence over years: fistulas trail grafts at 1 and 3 months (95.6/92.5%, 82.8/41.2%) then lead at 12 and 36 (14.2/15.8%, 8.2/15.0%) — but accumulate more catheter-days per year (80.1 vs 54.6) with less catheter-free time (78.1 vs 85.1%) — and the weighted target-trial finds fistula mortality and hospitalisation advantages only within 6 months (HR 0.82 each), fading thereafter.^[13][14] Pool the 75-plus verdict: autologous builds fail less at 24 months (OR 0.56) with forearm builds failing twice as often as upper-arm (OR 2.14 primary, 1.76 secondary) — so the elderly are not excluded from autogenous access, but the forearm is.^[15]

The choice resolution: attempt fistula first, graft where maturation odds or life expectancy forbid waiting, catheter where both fail — and quote the Quinn pilot's no-harm signal with shared decision-making whenever the patient prefers the catheter.^[7][6]

Management — Maturation: predictors, assistance, and imaging honesty

Give the base rates exactly: 55.5% mature in the prospective cohort, 24% forearm and 11% upper-arm nonmaturation in Holland against 6% graft failure, 36.2% of US fistulas never used with 54.7% working by 4 months — so the consent conversation starts at roughly one-in-three never used.^[16][17][18] Give the predictors exactly: stroke history, advancing age and dialysis dependence lower maturation odds; female sex, small artery and vein, low albumin, diabetes and low systolic and diastolic pressures predict early failure; Dutch nonmaturation flags female sex, peripheral and cerebrovascular disease with veins below 2.5 mm — and the 2026 series adds death within a year, peripheral disease and median antecubital-vein configuration with 42% failing and balloon assistance marking (not rescuing) the doomed at 60% technical success.^{[16][20][17][21]} Give the process levers exactly: HFM cannulation attempted in 90.2% with 97.1% eventual success and 88.6% overall maturation (61.2% unassisted, 27.4% assisted) — with access coordinators nearly doubling unassisted odds (OR 1.91) — so the unit's process is part of the prescription.^[19] Give the imaging honesty exactly: mapping chooses vessels by duplex, but 4 small randomised trials show no gain in creation, maturation, successful use or catheter avoidance — so image to plan, never to promise.^[22] Give the anaesthesia lever exactly: brachial plexus block lifts 3-month primary patency from 62 to 84% overall (OR 3.3) and 48 to 77% in radiocephalic builds (OR 3.6) — holding at 12 months (79 vs 59% primary, OR 2.7; 68 vs 49% functional, OR 2.1) with £195 saved per patient — pooled across 4 trials at 12 versus 36 failures (OR 0.28) — so the block is therapy, not comfort.^[59][60][61]

The maturation resolution: predict with the risk list, assist deliberately, block regionally — and never order mapping as a maturation guarantee.^{[16][19][59][22]}

Management — Cannulation: rope-ladder by default with buttonhole priced

Give the default exactly: rope-ladder is the in-centre standard because no evidence supports preferential buttonhole in facility or home dialysis — observational pain reduction (SMD -0.76) vanishes in randomised trials (SMD 0.34) — so pain alone never justifies the switch.^[45] Give the buttonhole benefits exactly: aneurysm formation falls to 0.18, stenosis to 0.44, thrombosis to 0.4 and hematoma to 0.63 — real structural gains across 15 trials — but infection shows no difference only because confidence intervals span harm (≦6 months RR 2.17, beyond 6 months RR 2.7).^[46] Give the infection price exactly: national surveillance counts 2466 bloodstream with 3169 local infections across buttonhole months — S. aureus in half, 37% hospitalised — at adjusted 2.6-fold bloodstream and 1.5-fold local risk over rope-ladder — while home data show systemic infections statistically tied (IRR 2.71, ns) but total fistula infections nearly quadrupled (IRR 3.85).^[47][48] The cannulation resolution: rope-ladder in-centre, buttonhole for the difficult-to-access fistula with scrupulous technique — quoting the aneurysm gain beside the sepsis price.^[45][46][47]

Management — Catheter: complications, locks, and the exchange ladder

Give the complication burden exactly: Canadian 1-year bacteremia 9%, malfunction 15%, central stenosis 2%, any complication 30% at 1 year and 38% at 2 with 0.5% complication-attributable death — paradoxically lower in septuagenarians and octogenarians (HR 0.67/0.69) — while Spanish 14-year bacteremia runs 0.40 per 1000 days, mostly Gram-positive (epidermidis 48.4%, aureus 28.0%) with 8.7% 30-day mortality from the first episode.^[49][50] Give the risk cluster exactly: age, diabetes, dialysis vintage, cirrhosis and femoral site predict bloodstream infection — with diabetic HbA1c 9.350 as the ROC threshold — so avoid the groin and shorten the catheter career.^[51] Give the lock regimens exactly as studied: minocycline-EDTA beats heparin at 1.1 against 4.3 per 1000 days with superior bacteremia-free survival — and gentamicin-citrate beats heparin at 0.45 against 1.68 (73% lower, RR 0.23 adjusted) — so the lock is prophylaxis with trial numbers, not ritual.^[52][53] Give the exchange ladder exactly as studied: clean-tunnel minimal symptoms earn guidewire exchange within 48 hours of antibiotics (87.8% cure), tunnel infection earns new-tunnel exchange (75%), severe sepsis earns removal with delayed replacement (86.5%) — all followed by 3 weeks of culture-directed antibiotics to a 45-day symptom-free cure definition.^[54]

The catheter resolution: minimise dwell, lock by evidence, exchange by appearance — and place the permanent access contralateral to the catheter's central damage.^{[51][52][54][55]}

Management — Steal: grade it, then DRIL it

Give the recognition exactly: steal complicates up to 10% of creations — brachial origin in 87% of treated episodes and 69% of ischaemic steals, women at 62 to 66%, diabetes at 61%, with coronary disease, hypertension and tobacco as risk factors — so the painful brachial-circuit hand is steal until disproven.^[37][33][34] Give the severity split exactly: grade-2 and grade-3 divide evenly in the surgical series — while severe grade-3 concentrates tissue loss (61%) over rest pain (39%) with diabetes at 86% and symptomatic peripheral disease at 63% — so tissue loss with a brachial fistula is grade 3 by presentation.^[33][35] Give the treatment ladder exactly by preservation: ligation 0%, DRIL 100%, RUDI 95%, banding 89% — with symptom improvement 98% for DRIL against 75% for banding, banding failing in 62% and driving reintervention, and RUDI matching DRIL on 12- and 36-month patency (58/55%, 51/41%) — so DRIL is preferred where the patient tolerates a major operation, RUDI where less invasiveness matters, and banding almost never.^[33][34][35] Give the conduit exactly: arm vein matches saphenous on 12- and 24-month access patency (86.9/82.0 vs 93.8/76.9%) with wound complications at 11 against 46% — under regional anaesthesia — so the ipsilateral arm vein is the conduit of choice where available.^[36] Give the prevention exactly: 5-to-6 mm anastomoses abolish steal (0 vs 9%) against 8-to-10 mm — trading 1-year primary patency (46.9 vs 67.9%) while assisted, secondary and functional patency hold equal — so small anastomoses suit small veins and steal-prone hands.^[37]

The steal resolution: observe mild, DRIL severe, ligate unsalvageable — and build small where steal threatens.^[34][33][37]

Management — Surveillance: fistula benefit, graft futility, threshold discipline

Give the Cochrane split exactly: preemptive correction halves thrombosis overall (RR 0.79) with imprecise loss effect (RR 0.81) — but subgrouping reveals the whole benefit lives in fistulas (thrombosis RR 0.5, loss RR 0.5) with grafts gaining nothing (0.95/0.9) — and the overall conclusion stands: preemptive correction does not improve access longevity, with more procedures, possible more infection and mortality, and unclear net effects.^[38] Give the randomised fistula proofs exactly: flow surveillance cuts thrombosis from 0.099 to 0.022 per patient-year with assisted patency HR 0.23 — and from 0.086 to 0.025 with thrombosis-free HR 0.30 and secondary HR 0.49 — while the graft flow trial finds thrombosis tied at 0.41 versus 0.51 with no loss difference despite more interventions.^[40][41][43] Give the pooled discipline exactly: surveillance RR 0.73 overall, 0.55 in fistulas, 0.92 (no benefit) in grafts — with the threshold trial repairing above 500 mL/min for 3-fold thrombosis and loss reduction against waiting for 400.^[42][44] Give the thrombosed-access honesty exactly: 14 trials with 1176 participants find no intervention superior for failure, 30-day patency, technical success or harm — with only very-uncertain surgical-over-mechanical 30-day patency (RR 1.36) — while 6 graft trials find surgery and endovascular tied except single-study assisted patency favouring surgery (OR 3.03).^[63][64]

The surveillance resolution: survey fistula flow with preemptive repair, monitor grafts clinically, and declot by availability — never by superiority claims.^[38][43][63]

Management — Graft patency, reintervention economy, and endovascular fistulas

Give the early-graft patency exactly by family: 12-month primary/secondary at 43.3/73.4% Flixene, 58.2/79.2% Avflo, 43.6/70.5% Acuseal and 63.7/85.8% Vectra — with all four permitting cannulation within 72 hours — so grafts live by reintervention and early use, not by durability.^[66] Give the reintervention economy exactly: 720 matured fistulas with 56% intervened at a median 12.6 months — open reintervention costs $357,143 per QALY after the first and $95,876 after the second, percutaneous $1.5 million down to $443,243 — so a new fistula becomes cost-effective after the second open reintervention while percutaneous persistence stays cheaper than rebuilding.^[65] Give the endovascular fistula exactly: pooled technical success 97% with maturation 77 to 82%, 6-month patency 64% with 12-month 77%, complications 9% — no different from surgery on success, failure, cannulation time or complications in direct comparison — with Ellipsys numerically ahead of WavelinQ on secondary patency (92.12 vs 81.36%) and abandonment (11.13 vs 32.54%).^[69][67][68] Give the adjuvant honesty exactly: 15 drug trials with 2230 participants — only ticlopidine favours treatment (OR 0.45) with aspirin, clopidogrel, elastase and fish oil all neutral — and aspirin at baseline paradoxically marks 84% less graft thrombosis in one multivariate model, a confounded association, never a prescription.^[62][43]

Complications & Pitfalls — the six traps

The maturation promise trap — booking a fistula without quoting the one-in-three never-used rate or the predictor list, when national data show 36.2% never used and Dutch data flag veins below 2.5 mm; consent the catheter months alongside the fistula plan.^[18][17]

The causal catheter trap — presenting catheter mortality hazard ratios as proof that catheters kill, when no completed randomised comparison exists and the only pilot shows no harm signal with most outcomes favouring catheters; counsel confounding and let strong preferences decide.^[6][1]

The buttonhole default trap — needling in-centre fistulas by buttonhole for pain or habit, when randomised trials erase the pain gain and surveillance prices bloodstream infection at 2.6-fold with S. aureus in half; reserve buttonhole for difficult access with disclosed sepsis arithmetic.^[45][47]

The graft surveillance trap — enrolling grafts in flow surveillance with preemptive repair, when thrombosis and loss ratios sit at 0.95 and 0.9 against deferred salvage and the randomised flow trial finds no loss difference despite more procedures; survey fistulas, monitor grafts.^[38][43]

The banding durability trap — banding steal expecting a lasting fix, when failure reaches 62% with reintervention driven and DRIL preserves 100% with 98% symptom improvement; banding is the reintervention generator, DRIL the default.^[34][33]

The ipsilateral convenience trap — placing the permanent access on the catheter side for convenience, when cumulative fistula survival more than doubles its hazard at 2.48; the contralateral arm is the plan, and central stenosis is imaged, not assumed.^[55][56]

Prognosis & Disposition — the numbers that set expectations

^{[1] [3] [18] [16] [22] [17] [9] [12] [15] [33] [34] [37] [38] [44] [47] [53] [54]}

Special Populations — contexts that change the emphasis

The elderly patient inherits separate pricing: fistula benefit survives past 70 but graft benefit dies past 90 and with comorbidity, predialysis creation reaches dialysis without a working access in half, and fistula-versus-graft trades early failure against infection and death — so age reweights every default without forbidding autogenous builds, except in the forearm past 75.^{[9][10][12][15]} The pacemaker patient inherits central vigilance: lead-induced stenosis holds only 18% primary patency against 95% secondary at the price of 2.1 yearly procedures — so ipsilateral access with a device earns central imaging and a patency-maintenance plan.^[56] The catheter-bridged patient inherits side discipline: ipsilateral history more than doubles the cumulative fistula hazard while leaving primary failure unchanged — so the new access goes contralateral and the old catheter comes out on schedule.^[55] The small-veined steal-prone hand inherits a small anastomosis: 5-to-6 mm builds abolish steal with equal functional patency despite lower primary numbers — so the at-risk hand is built small deliberately.^[37] The catheter-dependent patient with strong preferences inherits shared decision-making: the pilot's no-harm signal with most outcomes favouring catheters plus explicit preference data means the informed catheter choice is respected, not overruled.^[6]

Evidence, Guidelines & Regional Differences — the five stories and who led them

The access-type story is Ravani-to-Quinn: pooled hazards rank fistula over graft over catheter across 586,337 participants, CHOICE and Scotland and DOPPS replicate with conversion arithmetic both directions, decision analysis and cost-utility defend the attempt — and the pilot reminds that no efficacy randomisation exists.^{[1][2][4][3][7][8][6]} The maturation story is Feldman-to-HFM: predictors price the attempt, Dutch and US cohorts count the failures, HFM proves process matters with coordinators doubling unassisted odds, Cochrane denies imaging any gain, and regional anaesthesia earns its place as therapy.^{[16][17][18][19][22][59]} The configuration story is distal-to-proximal: Ryu justifies the forearm start, Kakkos randomises staging, VQI and pooling reconcile one-against-two, elevation beats tunnelling early, transposed fistulas beat grafts while the big pooling grants fistulas their failure paradox, and endovascular builds match surgery technically.^{[23][29][31][32][28][27][69]} The steal story is Leake-to-Turner: brachial risk recognised, severity graded, DRIL preferred with arm-vein conduit, RUDI matched where less invasiveness matters, banding discredited, and small anastomoses preventing — a complete ladder from a decade of series.^{[33][34][35][36][37]} The maintenance story is Cochrane-to-locks: preemptive repair split by access type, flow thresholds disciplined, thrombosed-access uncertainty confessed, buttonhole priced, locks and exchanges laddered — with guidelines criticised as opinion-based even as KDOQI GRADEs the Life-Plan.^{[38][44][63][47][52][54][57][58]} The stated honesty of this set: no guideline PDF bytes were fetched, so KDOQI claims are the guideline abstract's own words and every number belongs to a trial, meta-analysis or cohort abstract — regional practice varies, so name the study beside every protocol claim.^[57][58]

Exam Pearls — the one-liners that score

• Hierarchy: catheter 1.53 / graft 1.18 mortality vs fistula; fatal infection 2.12 / 1.36; no RCT exists — pilot shows no harm signal.^[1][6]
• Conversion: 69.2% start catheter; 22% permanent-access failure; conversion to permanent 0.69, back to catheter 1.81.^[3]
• Choice: attempt wins most phenotypes (Drew); $9389/QALY while maturation over 36%, dominant over 69%.^[7][8]
• Elderly: fistula benefit past 70 (0.56/0.55/0.69); graft dies past 90; predialysis reaches dialysis access-less in half; AVF-vs-graft trades 51/45% failure against 0.93/0.90/0.76 outcomes.^[9][10][12]
• Dependence: AVF trails at 1-3 months, leads at 12-36, yet banks more catheter-days (80.1 vs 54.6); target-trial wins fade past 6 months; 75-plus forearm fails 2x.^[13][14][15]
• Maturation: 55.5% mature; 24/11% Dutch fail; 36.2% never used; HFM 88.6% with coordination OR 1.91; imaging changes nothing; block lifts patency OR 3.3.^{[16][17][18][19][22][59]}
• Configurations: BC flow 492 vs 307 with patency 88.7/62.9; staged 100 vs 33% with trial stopped; VQI adjusted patency tied; elevation beats tunnel at 6 months.^{[23][29][31][32]}
• Fistula-vs-graft: primary failure OR 2.05 with patency wins; 1-year OR 1.61/1.69/1.69 with complications 0.52 and mortality 0.57; transposed beats graft on clot and sepsis.^[26][27][28]
• Steal: brachial 87%; DRIL 100/98 vs banding 89/75 with 62% failure; RUDI matches DRIL; arm vein 11 vs 46% wounds; small anastomosis 0 vs 9%.^{[33][34][35][36][37]}
• Surveillance: fistula 0.5/0.5, graft 0.95/0.9; flow trials 0.022/0.099 and 0.025/0.086; threshold above 500 triples benefit; thrombosed access has no superior declot.^{[38][40][41][44][63]}
• Cannulation: rope-ladder default; buttonhole aneurysm 0.18 with BSI aRR 2.6 and S. aureus in half; home systemic tied, total quadrupled.^{[45][46][47][48]}
• Catheter: 1-year 9/15/2% with 30/38% any; 0.40/1000 days with 8.7% first-episode death; femoral and HbA1c 9.350 flag; locks cut 73%+; exchange ladder 87.8/75/86.5%.^{[49][50][51][52][53][54]}
• Strategy: ipsilateral catheter doubles cumulative hazard (2.48); pacemaker angioplasty 18/95% primary/secondary; endoAVF 97/77% with 9% complications; reintervene twice open then rebuild.^{[55][56][69][65]}

Time predialysis exactly: 67/71% reach dialysis in 2 years; half start access-less; 46.8% placed within 90 days; catheter dependence 46.0 vs 28.5% fistula-vs-graft (PMID 25855782).^[10] Block exactly: plexus block 84 vs 62% at 3 months (OR 3.3; RC 77 vs 48%, OR 3.6), 79 vs 59% at 12 months (OR 2.7) with £195 saved; pooled 12 vs 36 failures (OR 0.28) (PMIDs 27492881/32709710/28285956).^[33]

References69ShowHide

1. [1]Ravani P, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol, 2013.PMID 23431075
2. [2]Astor BC, et al. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol, 2005.PMID 15788468
3. [3]Bradbury BD, et al. Conversion of vascular access type among incident hemodialysis patients: description and association with mortality. Am J Kidney Dis, 2009.PMID 19268411
4. [4]Bray BD, et al. Vascular access type and risk of mortality in a national prospective cohort of haemodialysis patients. QJM, 2012.PMID 22908320
5. [5]Ng LJ, et al. Hospitalization risks related to vascular access type among incident US hemodialysis patients. Nephrol Dial Transplant, 2011.PMID 21372255
6. [6]Quinn RR, et al. Comparing Catheters with Fistulas in Older Patients Starting Hemodialysis: A Pilot Randomized Controlled Trial. J Am Soc Nephrol, 2026.PMID 42319856
7. [7]Drew DA, et al. Vascular access choice in incident hemodialysis patients: a decision analysis. J Am Soc Nephrol, 2015.PMID 25063436
8. [8]Rosas SE, et al. Synthetic vascular hemodialysis access versus native arteriovenous fistula: a cost-utility analysis. Ann Surg, 2012.PMID 21918428
9. [9]DeSilva RN, et al. Association between initial type of hemodialysis access used in the elderly and mortality. Hemodial Int, 2012.PMID 22487417
10. [10]Lee T, et al. Outcomes of Elderly Patients after Predialysis Vascular Access Creation. J Am Soc Nephrol, 2015.PMID 25855782
11. [11]Lee T, et al. Vascular Access Type and Clinical Outcomes among Elderly Patients on Hemodialysis. Clin J Am Soc Nephrol, 2017.PMID 28798220
12. [12]Lee T, et al. Tradeoffs in Vascular Access Selection in Elderly Patients Initiating Hemodialysis With a Catheter. Am J Kidney Dis, 2018.PMID 29784614
13. [13]Lyu B, et al. Catheter Dependence After Arteriovenous Fistula or Graft Placement Among Elderly Patients on Hemodialysis. Am J Kidney Dis, 2021.PMID 33582176
14. [14]Lyu B, et al. Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach. Am J Kidney Dis, 2022.PMID 34118301
15. [15]Alexandra N, et al. A meta-analysis of vascular access outcomes in hemodialysis patients aged 75 years or older. J Vasc Access, 2024.PMID 36447351
16. [16]Feldman HI, et al. Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis, 2003.PMID 14582044
17. [17]Voorzaat BM, et al. Arteriovenous Fistula Maturation Failure in a Large Cohort of Hemodialysis Patients in the Netherlands. World J Surg, 2018.PMID 29188313
18. [18]Woodside KJ, et al. Arteriovenous Fistula Maturation in Prevalent Hemodialysis Patients in the United States: A National Study. Am J Kidney Dis, 2018.PMID 29429750
19. [19]Allon M, et al. Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study. Am J Kidney Dis, 2018.PMID 29398178
20. [20]Salih SSM, et al. Predictors of early arteriovenous fistula failure in patients with end stage renal disease on hemodialysis: a systematic review and meta-analysis. Patient Saf Surg, 2025.PMID 40898218
21. [21]Fisher AT, et al. Predictors of maturation failure in arteriovenous dialysis access. J Vasc Surg, 2026.PMID 40930312
22. [22]Kosa SD, et al. Preoperative vascular access evaluation for haemodialysis patients. Cochrane Database Syst Rev, 2015.PMID 26418347
23. [23]Ryu YG, et al. Outcomes of Autogenous Radiocephalic Versus Brachiocephalic Arteriovenous Fistula Surgery Based on Transit-Time Flowmeter Assessment: A Retrospective Study. Ann Vasc Surg, 2022.PMID 34936890
24. [24]Hu D, et al. A modified nontransposed brachiobasilic arteriovenous fistula versus brachiocephalic arteriovenous fistula for maintenance hemodialysis access. J Vasc Surg, 2016.PMID 27296523
25. [25]Lu E, et al. Outcomes of prosthetic upper arm arteriovenous graft vs brachiobasilic fistula for hemodialysis access. J Vasc Surg, 2024.PMID 38909916
26. [26]Hajibandeh S, et al. Impact of arteriovenous fistulas versus arteriovenous grafts on vascular access performance in haemodialysis patients: A systematic review and meta-analysis. Vascular, 2022.PMID 34461784
27. [27]Yang C, et al. Comparative outcomes of arteriovenous fistulas and grafts in haemodialysis: meta-analysis with subgroup analysis by fistula type and transposition status. BJS Open, 2025.PMID 41921109
28. [28]Tang QH, et al. Comparison between transposed arteriovenous fistulas and arteriovenous graft for the hemodialysis patients: A meta-analysis and systematic review. J Vasc Access, 2024.PMID 35708346
29. [29]Kakkos SK, et al. Randomized controlled trial comparing primary and staged basilic vein transposition. Front Surg, 2015.PMID 25973421
30. [30]Jun Yan Wee I, et al. A systematic review and meta-analysis of one-stage versus two-stage brachiobasilic arteriovenous fistula creation. J Vasc Surg, 2018.PMID 29937034
31. [31]Tan TW, et al. Comparison of one-stage and two-stage upper arm brachiobasilic arteriovenous fistula in the Vascular Quality Initiative. J Vasc Surg, 2019.PMID 30301685
32. [32]Koudounas G, et al. Basilic vein tunnel transposition versus elevation transposition for brachiobasilic arteriovenous fistula creation: A systematic review and meta-analysis. J Vasc Access, 2025.PMID 38336667
33. [33]Leake AE, et al. Management and outcomes of dialysis access-associated steal syndrome. J Vasc Surg, 2015.PMID 25499703
34. [34]Gupta N, et al. Treatment strategies of arterial steal after arteriovenous access. J Vasc Surg, 2011.PMID 21276691
35. [35]Misskey J, et al. A comparison of revision using distal inflow and distal revascularization-interval ligation for the management of severe access-related hand ischemia. J Vasc Surg, 2016.PMID 26776897
36. [36]Weaver ML, et al. Distal revascularization and interval ligation for dialysis access-related ischemia is best performed using arm vein conduit. J Vasc Surg, 2021.PMID 32882351
37. [37]Turner MA, et al. Small Arteriovenous Anastomosis in Fistula Creation: Establishing a Functional Vascular Access while Minimizing Steal Syndrome. Ann Vasc Surg, 2024.PMID 37926140
38. [38]Ravani P, et al. Pre-emptive correction for haemodialysis arteriovenous access stenosis. Cochrane Database Syst Rev, 2016.PMID 26741512
39. [39]Ravani P, et al. Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Kidney Dis, 2016.PMID 26776537
40. [40]Aragoncillo I, et al. The impact of access blood flow surveillance on reduction of thrombosis in native arteriovenous fistula: a randomized clinical trial. J Vasc Access, 2016.PMID 26391583
41. [41]Aragoncillo I, et al. Adding access blood flow surveillance reduces thrombosis and improves arteriovenous fistula patency: a randomized controlled trial. J Vasc Access, 2017.PMID 28430315
42. [42]Ali H, et al. Effects of hemodialysis access surveillance on reducing risk of hemodialysis access thrombosis: A meta-analysis of randomized studies. Hemodial Int, 2021.PMID 33759341
43. [43]Moist LM, et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol, 2003.PMID 14514744
44. [44]Tessitore N, et al. Pro: Vascular access surveillance in mature fistulas: is it worthwhile? Nephrol Dial Transplant, 2019.PMID 30768204
45. [45]Wong B, et al. Buttonhole versus rope-ladder cannulation of arteriovenous fistulas for hemodialysis: a systematic review. Am J Kidney Dis, 2014.PMID 25110302
46. [46]Wang LP, et al. Effect of buttonhole cannulation versus rope-ladder cannulation in hemodialysis patients with vascular access: A systematic review and meta-analysis of randomized/clinical controlled trials. Medicine (Baltimore), 2022.PMID 35866782
47. [47]Lyman M, et al. Risk of Vascular Access Infection Associated With Buttonhole Cannulation of Fistulas: Data From the National Healthcare Safety Network. Am J Kidney Dis, 2020.PMID 32151430
48. [48]Muir CA, et al. Buttonhole cannulation and clinical outcomes in a home hemodialysis cohort and systematic review. Clin J Am Soc Nephrol, 2014.PMID 24370768
49. [49]Poinen K, et al. Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study. Am J Kidney Dis, 2019.PMID 30642607
50. [50]Almenara-Tejederas M, et al. Tunneled catheter-related bacteremia in hemodialysis patients: incidence, risk factors and outcomes. A 14-year observational study. J Nephrol, 2023.PMID 35976569
51. [51]Arslan M, et al. Tunneled Catheter-Related Bloodstream Infections in Chronic Hemodialysis Patients: Frequency, Risk Factors, and Outcomes-A 10-Year Analysis. APMIS, 2025.PMID 40078110
52. [52]Campos RP, et al. Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis. J Am Soc Nephrol, 2011.PMID 21852579
53. [53]Moore CL, et al. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients. Clin J Am Soc Nephrol, 2014.PMID 24970874
54. [54]Beathard GA Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol, 1999.PMID 10232691
55. [55]Shingarev R, et al. Association of hemodialysis central venous catheter use with ipsilateral arteriovenous vascular access survival. Am J Kidney Dis, 2012.PMID 22824354
56. [56]Asif A, et al. Patency rates for angioplasty in the treatment of pacemaker-induced central venous stenosis in hemodialysis patients: results of a multi-center study. Semin Dial, 2009.PMID 19799756
57. [57]Lok CE, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis, 2020.PMID 32778223
58. [58]Sequeira A, et al. Vascular Access Guidelines: Summary, Rationale, and Controversies. Tech Vasc Interv Radiol, 2017.PMID 28279405
59. [59]Aitken E, et al. Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial. Lancet, 2016.PMID 27492881
60. [60]Aitken E, et al. Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial. J Am Soc Nephrol, 2020.PMID 32709710
61. [61]Cerneviciute R, et al. Regional Versus Local Anaesthesia for Haemodialysis Arteriovenous Fistula Formation: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg, 2017.PMID 28285956
62. [62]Tanner NC, et al. Medical Adjuvant Treatment to Improve the Patency of Arteriovenous Fistulae and Grafts: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg, 2016.PMID 27289558
63. [63]Fonseca AV, et al. Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts. Cochrane Database Syst Rev, 2024.PMID 38353936
64. [64]Kuhan G, et al. A meta-analysis of randomized trials comparing surgery versus endovascular therapy for thrombosed arteriovenous fistulas and grafts in hemodialysis. Cardiovasc Intervent Radiol, 2013.PMID 23381773
65. [65]Brooke BS, et al. Cost-effectiveness of repeated interventions on failing arteriovenous fistulas. J Vasc Surg, 2019.PMID 31147114
66. [66]Al Shakarchi J, et al. Early cannulation grafts for haemodialysis: An updated systematic review. J Vasc Access, 2019.PMID 29843554
67. [67]Malik MH, et al. Endovascular Versus Surgical Arteriovenous Fistulas: A Systematic Review and Meta-analysis. Kidney Med, 2022.PMID 35386608
68. [68]Bontinis A, et al. A systematic review aggregated data and individual participant data meta-analysis of percutaneous endovascular arteriovenous fistula. J Vasc Surg, 2023.PMID 36328141
69. [69]Ameen NK, et al. Endovascular arteriovenous fistula: Outcomes and comparison with surgical arteriovenous fistula: An updated systematic review and meta-analysis. J Vasc Access, 2026.PMID 41882540